According to the information received:
"The EPO revocation was based in part on Novozymes’ own documents (obtained by disclosure in the United Kingdom and released for use in the EPO by the Patents Court for England and Wales), which undermined Novozymes’ submissions in the EPO. This revocation restores the ability of Danisco -- acquired by DuPont in May 2011 -- to engage in commercial activities in Europe and provide customers with innovative solutions in the animal feed business.This does not mean that the matter is at an end:
This decision sheds light on the discussions concerning the impending unitary patent in Europe, because it emphasises the importance of UK-style disclosure in determining the validity of commercially important patents. Novozymes initially refused to allow the documents to be used in the EPO. However, the decision of the Patents Court at  EWHC 696 (Pat) [this is not yet available online on BAILII] made the crucial documents available. The Patents Court and Court of Appeal initially refused to make the documents available to the EPO, but this position changed after Novozymes was held to be at fault in requesting a late adjournment of the UK trial. The decision also indicates the speed with which the EPO can decide accelerated proceedings: the patent was granted on 11 November 2009, opposed on 30 March 2010, revoked by the Opposition Division on 7 July 2011 and finally revoked by the Technical Board of Appeal on 29 June 2012 (31.5 months from grant to final revocation)".
"Danisco will also seek compensation for the damage caused by a preliminary injunction originally obtained by Novozymes in Denmark. On May 25, 2012, before the Technical Board of Appeal revoked the EP'592 patent, the Eastern High Court in Copenhagen had revoked that preliminary injunction and ordered Novozymes to pay Danisco 1.5 million DKK (Danish kroner) in legal costs".